Longitudinal evaluation of serum androgen levels in men with and without prostate cancer

H. Ballentine Carter, Jay D. Pearson, E. Metter, Daniel W. Chan, Reubin Andres, James L. Fozard, William Rosner, Patrick C. Walsh

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Androgens are thought to play a role in the pathogenesis of prostate cancer. We evaluated androgen levels in 3 age‐matched groups of men who were part of the Baltimore Longitudinal Study of Aging: 1) 16 men with no prostatic disease by urologic history and exam (control group); 2) 20 men with a histologic diagnosis of benign prostatic hyperplasia (BPH) who had undergone simple prostatectomy; and 3) 20 men with a histologic diagnosis of prostate cancer (16 with local/regional cancer, and 4 with metastatic cancer). Luteinizing hormone (LH), total testosterone (T), and free T were measured on stored AM sera by radioimmunoassay (RIA). Free T was also calculated from the measured concentrations of total T and sex hormone binding globulin (SHBG). The median number of repeated sex steroid measurements ranged from 6–9 over a period from 7–25 years prior to the diagnosis of prostate disease. There were no significant differences in age‐adjusted LH, total T, SHBG, or calculated free T levels among the groups at 0–5, 5–10, and 10–15 years before diagnosis. These data suggest that there are no measurable differences in serum testosterone levels among men who are destined to develop prostate cancer and those without the disease. © 1995 Wiley‐Liss, Inc.

Original languageEnglish (US)
Pages (from-to)25-31
Number of pages7
JournalThe Prostate
Volume27
Issue number1
DOIs
StatePublished - Jan 1 1995

Fingerprint

Androgens
Prostatic Neoplasms
Serum
Sex Hormone-Binding Globulin
Luteinizing Hormone
Testosterone
Prostatic Diseases
Baltimore
Prostatic Hyperplasia
Prostatectomy
Radioimmunoassay
Longitudinal Studies
Prostate
Neoplasms
History
Steroids
Control Groups

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

Cite this

Carter, H. B., Pearson, J. D., Metter, E., Chan, D. W., Andres, R., Fozard, J. L., ... Walsh, P. C. (1995). Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. The Prostate, 27(1), 25-31. https://doi.org/10.1002/pros.2990270106

Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. / Carter, H. Ballentine; Pearson, Jay D.; Metter, E.; Chan, Daniel W.; Andres, Reubin; Fozard, James L.; Rosner, William; Walsh, Patrick C.

In: The Prostate, Vol. 27, No. 1, 01.01.1995, p. 25-31.

Research output: Contribution to journalArticle

Carter, HB, Pearson, JD, Metter, E, Chan, DW, Andres, R, Fozard, JL, Rosner, W & Walsh, PC 1995, 'Longitudinal evaluation of serum androgen levels in men with and without prostate cancer', The Prostate, vol. 27, no. 1, pp. 25-31. https://doi.org/10.1002/pros.2990270106
Carter, H. Ballentine ; Pearson, Jay D. ; Metter, E. ; Chan, Daniel W. ; Andres, Reubin ; Fozard, James L. ; Rosner, William ; Walsh, Patrick C. / Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. In: The Prostate. 1995 ; Vol. 27, No. 1. pp. 25-31.
@article{2d8f132a034a4dc1adc0c09dfbc7872d,
title = "Longitudinal evaluation of serum androgen levels in men with and without prostate cancer",
abstract = "Androgens are thought to play a role in the pathogenesis of prostate cancer. We evaluated androgen levels in 3 age‐matched groups of men who were part of the Baltimore Longitudinal Study of Aging: 1) 16 men with no prostatic disease by urologic history and exam (control group); 2) 20 men with a histologic diagnosis of benign prostatic hyperplasia (BPH) who had undergone simple prostatectomy; and 3) 20 men with a histologic diagnosis of prostate cancer (16 with local/regional cancer, and 4 with metastatic cancer). Luteinizing hormone (LH), total testosterone (T), and free T were measured on stored AM sera by radioimmunoassay (RIA). Free T was also calculated from the measured concentrations of total T and sex hormone binding globulin (SHBG). The median number of repeated sex steroid measurements ranged from 6–9 over a period from 7–25 years prior to the diagnosis of prostate disease. There were no significant differences in age‐adjusted LH, total T, SHBG, or calculated free T levels among the groups at 0–5, 5–10, and 10–15 years before diagnosis. These data suggest that there are no measurable differences in serum testosterone levels among men who are destined to develop prostate cancer and those without the disease. {\circledC} 1995 Wiley‐Liss, Inc.",
author = "Carter, {H. Ballentine} and Pearson, {Jay D.} and E. Metter and Chan, {Daniel W.} and Reubin Andres and Fozard, {James L.} and William Rosner and Walsh, {Patrick C.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1002/pros.2990270106",
language = "English (US)",
volume = "27",
pages = "25--31",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Longitudinal evaluation of serum androgen levels in men with and without prostate cancer

AU - Carter, H. Ballentine

AU - Pearson, Jay D.

AU - Metter, E.

AU - Chan, Daniel W.

AU - Andres, Reubin

AU - Fozard, James L.

AU - Rosner, William

AU - Walsh, Patrick C.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Androgens are thought to play a role in the pathogenesis of prostate cancer. We evaluated androgen levels in 3 age‐matched groups of men who were part of the Baltimore Longitudinal Study of Aging: 1) 16 men with no prostatic disease by urologic history and exam (control group); 2) 20 men with a histologic diagnosis of benign prostatic hyperplasia (BPH) who had undergone simple prostatectomy; and 3) 20 men with a histologic diagnosis of prostate cancer (16 with local/regional cancer, and 4 with metastatic cancer). Luteinizing hormone (LH), total testosterone (T), and free T were measured on stored AM sera by radioimmunoassay (RIA). Free T was also calculated from the measured concentrations of total T and sex hormone binding globulin (SHBG). The median number of repeated sex steroid measurements ranged from 6–9 over a period from 7–25 years prior to the diagnosis of prostate disease. There were no significant differences in age‐adjusted LH, total T, SHBG, or calculated free T levels among the groups at 0–5, 5–10, and 10–15 years before diagnosis. These data suggest that there are no measurable differences in serum testosterone levels among men who are destined to develop prostate cancer and those without the disease. © 1995 Wiley‐Liss, Inc.

AB - Androgens are thought to play a role in the pathogenesis of prostate cancer. We evaluated androgen levels in 3 age‐matched groups of men who were part of the Baltimore Longitudinal Study of Aging: 1) 16 men with no prostatic disease by urologic history and exam (control group); 2) 20 men with a histologic diagnosis of benign prostatic hyperplasia (BPH) who had undergone simple prostatectomy; and 3) 20 men with a histologic diagnosis of prostate cancer (16 with local/regional cancer, and 4 with metastatic cancer). Luteinizing hormone (LH), total testosterone (T), and free T were measured on stored AM sera by radioimmunoassay (RIA). Free T was also calculated from the measured concentrations of total T and sex hormone binding globulin (SHBG). The median number of repeated sex steroid measurements ranged from 6–9 over a period from 7–25 years prior to the diagnosis of prostate disease. There were no significant differences in age‐adjusted LH, total T, SHBG, or calculated free T levels among the groups at 0–5, 5–10, and 10–15 years before diagnosis. These data suggest that there are no measurable differences in serum testosterone levels among men who are destined to develop prostate cancer and those without the disease. © 1995 Wiley‐Liss, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0029033044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029033044&partnerID=8YFLogxK

U2 - 10.1002/pros.2990270106

DO - 10.1002/pros.2990270106

M3 - Article

C2 - 7541528

AN - SCOPUS:0029033044

VL - 27

SP - 25

EP - 31

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 1

ER -